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Summary Previous studies have shown that chronic hypoxia leads to changes in
skeletal muscle structure (fibre size and type) and activities of several bioenergetic
enzymes. Whether this occurs also in conditions characterised by intermittent
hypoxia, such as the obstructive sleep apnoea syndrome (OSAS), is unknown. To
explore this possibility, we obtained a needle biopsy of the quadriceps femoris in 12
consecutive stable outpatients with severe OSAS (5279 year, apnoea–hypopnoea
index 70714 h1) (x7SD) and in six healthy volunteers (4978 year), where we
quantified fibre type, size and protein content, as well as phosphofructo-kinase (PFK)
and cytochrome oxidase (CytOx) activities. We found that fibre-type distribution was
similar in patients and controls. In contrast, the diameter of type II fibres (74710 mm
vs. 56711 mm, Po0:05) and protein content (100714 vs. 8878mg/mg) was higher in
patients with OSAS. Likewise, we observed upregulation of CytOx (0.9370.38 vs.
0.4070.22 mkat/mg protein, Po0:01) and PFK activities (5.3574.8 vs. 1.371.3 mkat/
mg protein, Po0:05) in patients with OSAS. These results show that, paralleling which
occurs in conditions characterised by continuous hypoxia, patients with OSAS (and
intermittent hypoxia) also show structural and bioenergetic changes in their skeletal
muscle.







Chronic exposure to hypoxia leads to changes in
muscle structure (fibre size and type) and activity
of several bioenergetic enzymes. These changes
have been well characterised both in healthy
subjects living at altitude1,2 and in patients with
a variety of diseases characterised by chronic
hypoxia, including chronic heart failure (CHF),3
peripheral arterial disease4 and chronic obstructive
pulmonary disease (COPD).5–7 In these latter
patients, for instance, there is atrophy (de-
creased fibre size),8 a shift towards type II
fibres8 and increased activity of phosphofructo-
kinase (PFK), the rate-limiting glycolitic enzyme5
and cytochrome oxidase (CytOx) the terminal
enzyme of the mitochondrial electron transport
chain.7
Whether this occurs also in clinical conditions
characterised by intermittent (vs. chronic) expo-
sure to hypoxia is unknown. Patients with obstruc-
tive sleep apnoea syndrome (OSAS) offer a naturally
occurring example where to test this hypothesis
because it is characterised by the repetition of
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many episodes of arterial oxygen desaturation
followed by a rapid normalisation of oxygen
tension upon the restoration of ventilation.9,10 To
date, the only ‘‘skeletal’’ muscle studied in
patients with OSAS are those of the upper airway
(the genioglossus11 and the musculus uvulae12).
These previous studies have demonstrated that,
compared to controls, patients with OSAS showed a
shift towards type II fibres,12 higher glycolitic
enzyme activities12 and more in vitro fatigability.11
However, because upper airway muscles in these
patients are subjected to enormous mechanical
changes during sleep, these changes cannot be
directly attributed to hypoxia. Further, despite
that these abnormalities tend to improve with
treatment,11,12 given that the use of continuous
positive airway pressure (CPAP) prevents both
airway collapse and arterial desaturation, the
pathogenic responsibilities of the increased me-
chanical load vs. tissue hypoxia are impossible to
dissociate in vivo. To overcome this limitation, in
the present study we sought to compare the
structure (fibre-type, size and protein content)
and activity (PFK and CytOx activity) of a limb
muscle (quadriceps femoris) in patients with OSAS




We studied 12 consecutive stable outpatients with
OSAS (recently diagnosed and without CPAP ther-
apy) and six healthy volunteers of similar age and
smoking history (Table 1). To avoid potential
confounding factors, we studied only male seden-
tary subjects and we excluded patients with known
neuromuscular disorders, cardiac failure, diabetes
mellitus, alcoholism, COPD, daytime arterial hy-
poxemia (PaO2o75mmHg) and/or those receiving
treatment with oral steroids. In all patients, OSAS
was diagnosed by standard polysomnography (Ul-
trasom Nicolette, Madison, WI) according to na-
tional and international guidelines.13,14 Control
subjects were recruited from our respiratory unit.
In them OSAS was excluded on the basis of the
clinical history and sleep oximetry recording
(Biochem International Incorporated, Waukesha,
WI). All participants signed their informed consent
after being fully aware of the nature, character-
istics and risks of the study, which had been
approved by the Ethical Review Board of our
institution.
Lung function
Forced spirometry (GS W. Collins, USA) was
obtained in all participants.15 Reference values
were those of a Mediterranean population.16 Like-
wise, an arterial blood sample was obtained by
radial artery puncture under local anaesthesia. This
was immediately assayed for PaO2, PaCO2 and pH
(IL BG3, Izasa, Spain).
Muscle biopsy
Muscle biopsy was obtained 1–2 weeks after
polysomnography. A standard percutaneous needle
biopsy technique was used to obtain several (B4)
muscle samples from the lateral portion of muscle
quadriceps femoris (at the mid-thigh level), under
local anaesthesia, as previously reported in our
laboratory.7 Enzyme activities (PFK and CytOx)
were measured in fresh tissue. The remaining
tissue sample was frozen immediately after the
biopsy in isopentane (in liquid nitrogen) and stored
at 801C until analysis.
Measurement of enzymes activities
Fresh muscle samples were weighed (wet weight:
30–90mg) and homogenised in 250mM sucrose/
1mM HEPES/0.2mM EDTA buffer (pH 7.0) in a
Teflon/glass homogeniser, held in an ice bath.
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Table 1 Anthropometric and functional data












Body mass index (kg/m2) 3577 2874*
FEV1 (% reference) 85711 104710*
FEV1/FVC (%) 8476 8475
PaO2 (mmHg) 7978 8676




Mean nocturnal SaO2 (%) 82712 9772**
NA: not available. FEV1: forced expiratory volume in the
1st second; FVC: forced vital capacity; PaO2 and PaCO2:
day-time values of the arterial partial pressure values of
oxygen and carbon dioxide; SaO2: arterial oxyhemoglobin
saturation; *Po0:05;**Po0:01:
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Aliquots of this homogenate were assayed for total
protein content17 and CytOx activity (E.C.1.9.3.1).
The latter was determined at 371C according to the
protocol described by Wharton et al.,18 as pre-
viously described in our laboratory.7,19 The remain-
ing homogenate was sonicated in an ice bath for
1min, and then centrifuged at 2500 rpm, 41C for
5min. The pellet was discarded, and the super-
natant was used for the determination of the
activity of PFK (E.C.2.7.1.56),20 as well as soluble
protein content.18 All enzymatic activities were
measured in a Shimadzu spectrophotometer (Shi-
madzu, Nagoya, Japan) with continuos optical
absorbance register at 371C for 5min. All reagents
were obtained from Sigma Chemical Co (St. Louis,
MO, USA).
Muscle fibre-type analysis
Muscle samples were cut 6 mm thick in a cryostat
(201C). Type I (‘‘slow twitch’’) and II (‘‘fast
twitch’’) fibres were identified by the standard
adenosine triphosphate (ATPase) (at 9.4 and 4.6 pH
pre-incubation) and the standard reduced nicoti-
namine adenine dinucleotide tetrazolium (NADH-
TR), as described previously.21,22 Morphometric
evaluation was done using a semiautomatic system
(Sigmascan, Jandel Scientific, Erkrath, Germany).
Two independent observers quantified, in at least
100 fibres: (a) the percentage of type I and II fibres;
and (b) the least diameter for each fibre type,
which is minimally influenced by the cutting angle
during the sampling process.21,22
Statistical analysis
Results are shown as mean7SD. The reproducibility
of the morphometric measurements between the
two observers was tested using the intraclass
correlation coefficient.23 The Mann–Whitney test
was used to compare values measured in patients
and in controls. Potential relationships between
variables of interest were evaluated using the
Spearman coefficient. A P value lower than 0.05
was considered statistically significant.
Results
Table 1 shows the main anthropometric, smoking
history (all individuals were ex-smokers), lung
function and sleep variables determined in in-
patients with OSAS and in healthy subjects. Age was
similar in both groups. Patients were more obese
than healthy controls. Spirometry and arterial
blood gases were normal in both groups. All
patients with OSAS had and apnoea–hypopnoea
index (AHI) higher than 60 h1 and showed frequent
and profound episodes of arterial desaturation
during sleep. As expected, mean nocturnal arterial
oxygen saturation was lower (Po0:01) in patients
with OSAS (82712%) than in controls (9772%).
Because morphometric measurements were
highly concordant between the two observers
(r ¼ 0:92; Po0:01) we used average values for the
analysis. The percentage of fibre types was similar
in patients and controls (Table 2). Yet, fibre size
was higher in patients with OSAS, particularly that
of type II fibres (Table 2). Likewise, total muscle
protein content was higher in patients than in
control subjects (Table 2).
As shown in Fig. 1, patients with OSAS showed
higher CytOx (0.9370.38 vs. 0.4070.22 mkat/mg
protein, Po0:01) and PFK activities (5.3574.8 vs.
1.371.3 mkat/mg protein, Po0:05) than healthy
controls.
Neither the AHI nor the mean nocturnal SaO2
were significantly related to the morphometric
parameters (percentage and size of fibres) or to
the enzyme activities determined.
Discussion
This study shows that patients with OSAS present
structural (increased diameter of type II fibres and
increased protein content) and metabolic abnorm-
alities (upregulation of CytOx and PFK activities) in
their skeletal muscle.
Previous studies
To the best of our knowledge, no previous study
has investigated the structure and bioenergetic
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% Type I fibres 48712 50714
% Type II fibres 52712 50714
+ Type I fibres (m) 65711 5479




Abbreviations: +, diameter. *Po0:05 (compared to
controls).
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metabolism of skeletal (quadriceps femoris) muscle
in patients with OSAS. Yet, some previous reports
already suggested a potential alteration of muscle
bioenergetics in OSAS. For instance, Williams and
Moshenifar reported that oxygen uptake in these
patients increases in parallel to cardiac output and
suggested the presence of a pathological oxygen
supply dependency in OSAS.24 A later study by
Vanuxem et al reported that patients with OSAS
showed lower oxygen uptake and lower blood
lactate concentration during peak exercise than
healthy subjects (although this occurred at lower
exercise intensity), and also suggested the pre-
sence of impaired muscle energy metabolism.25
However, muscle biopsies were not obtained in any
of these two studies and, therefore, these hypoth-
eses could not be tested directly. Likewise, none of
them reported morphometric measurements in the
skeletal muscle in these patients.
Morphometric analysis
The percentage of the different fibre types in
patients with OSAS was not significantly different
from that seen in healthy subjects. These results
agree with several studies that have examined
muscle fibre-type proportions following exposure to
hypobaric hypoxia in healthy subjects.26,27 Gener-
ally, most of these studies have reported no
adaptations in fibre-type proportions. These ob-
servations contrast with those reported in diseases
characterised by chronic hypoxia, such as COPD28 or
chronic heart failure,29 where increases in type II
fibres have been described. Although this can be
due to the different type of hypoxic insult suffered
(chronic vs. intermittent), other factors cannot be
excluded. For example, at variance with the
patients with OSAS studied here with active life,
patients with COPD or CHF often adopt an extreme
sedentary life-style, which by its own can have a
significant impact on skeletal muscle structure.30
The diameter of muscle fibres, particularly that
of type II fibres (as well as their protein content),
was increased in patients with OSAS compared with
healthy subjects (Table 2). These observations
contrast with those reported in COPD28 or CHF,29
where reduced fibre size (atrophy) have been
described. Again we think this can be due to the
different type of hypoxic insult suffered (chronic
vs. intermittent) and deconditioning.30 On the
other hand, it is possible that the increased body
mass index (BMI) that characterises OSAS9 may have
also contributed to the higher muscle fibre size and
higher muscle protein content observed in the
present study.31 In theory, another factor that can
influence the increase in the size of type II fibres
observed here could be the activity pattern of the
patients. However, this is unlikely in our study
because both groups of subjects had a similar level
of physical activity.
Our results in limb muscle also contrast with
those previously reported in upper airway muscles
of patients with OSAS.11,12 In the latter muscles,
there seems to be an increase in the percentage of
type II fibres in OSAS. However, as discussed above,
these upper airway muscles in OSAS are exposed to
repetitive, short-lasted, maximal stress during
sleep, which can contribute to explain the increase
of type II fibres.11,12 In fact, the absence of such
changes in limb skeletal muscle suggests that such
mechanical stress, and not intermittent hypoxia, is
the main mechanism explaining them.
Enzyme activities
We found that the activities of CytOx and PFK were
higher in patients with OSAS than in healthy
controls (Fig. 1). Because the activity of oxidative
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Figure 1 Individual and mean (bars) values of CytOx and PFK activity in healthy subjects and in patients with OSAS.
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enzymes correlates directly with oxygen consump-
tion,32 the former observation is in keeping with
the increased resting energy expenditure described
in patients with OSAS.33 There are several mechan-
isms that can potentially explain the upregulation
in CytOx activity. (1) Hypoxia: because a similar
increase in CytOx activity has been described in
other clinical conditions characterised by contin-
uous tissue hypoxia, an obvious candidate is
intermittent hypoxia due to OSAS.4,7 Under these
circumstances, an increase in CytOx activity may
help to sustain metabolic flux rates by increasing
the blood to mitochondrion PO2 gradient.
34 At
variance with this possibility, however, we did not
find a significant correlation between the AHI or
mean nocturnal SaO2 and CytOx activity. Yet, it is
possible that the narrow range of disease severity
of the patients studied here (all of them with
severe OSAS) may have limited the possibility of
finding such relationship. It is also possible that
other variables, such as the area under the SaO2
curve at night, or the number of episodes of
desaturation may be better suited to estimate
tissue oxygenation in these patients.35 (2) Obesity:
despite that patients with OSAS were more obese
(higher BMI) than healthy subjects (Table 1), we
think that this is unlikely to explain our findings
because obesity reduces (not enhances) energy
expenditure,36 thus oxidative metabolism.32
Further, we did not find a significant correlation
between CytOx activity and BMI (data not shown).
(3) Level of physical activity: as we mentioned
above, patients and controls have similar activity
pattern and none of them participated in regular
sport activities, so differences in CytOx activities
cannot be explained by this factor. (4) Aging:
oxidative metabolism decreases with age.37 Yet,
patients and controls have similar age (Table 1) and
therefore aging cannot explain our findings. (5)
Smoking: several compounds of cigarette smoke
such as carbon monoxide and nitric oxide can
influence CytOx activity.38,39 However, none of the
subjects included were a current smokers. (6) Drug
effects: high doses of b2-agonists can increase
oxygen uptake (thus presumably, CytOx activity)40
and corticosteroids can induce miopathy.41 We
exclude these effects because none of the subjects
used them. And finally, (7) oxidative stress and
systemic inflammation: both have been described
in patients with OSAS42 and may therefore con-
tribute to these muscle abnormalities.19,43 This
possibility will have to be explored in future
studies.
With respect to PFK activity our results agree
with those reported in other situations of chronic
hypoxia, such as COPD and high altitude living.5,44
Therefore, the increased PFK activity observed in
our patients with OSAS can be explained by their
intermittent exposure to hypoxia during sleep. This
change can be viewed as an adaptive mechanism
aimed at facilitating glycolitic oxidation under
hypoxic conditions.5 These results, however, con-
trast with those of Series et al. who did not find
significant differences in genioglossus of patients
with OSAS compared with chronic snorers.12 How-
ever, in terms of the mechanical conditions of the
genioglossus, snorers cannot be considered
‘‘healthy’’ controls. Further, as discussed above,
the genioglossus in patients with OSAS is exposed to
heavy mechanical forces during sleep that can
clearly interfere with enzyme activities.12 Thus,
our results suggest that intermittent hypoxia in
OSAS upregulates PFK activity in limb muscles.
Our results differ from those reported at extreme
high altitude in healthy subjects (45000m), where
a decrease in oxidative metabolism with minimal
changes in glycolitic enzymes have been re-
ported.1,26 However, they are in keeping with
findings at moderately high altitude (3.500–
5.000m), where upregulation of these enzymes
like that seen in our study, have been described.2,44
Also, studies of oxidative enzymes in peripheral
muscle of hypoxic patients with COPD7 or periph-
eral arterial disease4 have also shown similar
results. Finally, it has to be kept in mind that
patients with OSAS are submitted to intermittent
hypoxia whereas subjects at high altitude are
exposed to continuous hypoxia, a factor that can
also contribute to the observed differences.
Conclusions
Our study shows that skeletal muscle structure
(increased muscle fibre size and protein content)
and bioenergetics (upregulated CytOx and PFK
activities) are abnormal in patients with OSAS.
The functional implications of these observations,
as well as their potential reversibility with CPAP
treatment and the precise underlying mechanisms
will have to be elucidated in future studies.
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